Prescription drug monitoring programs are associated with sustained reductions in opioid prescribing by physicians

Health Affairs

Volumn 35, Issue 6, 2016, Pages 1045-1051

  Bao, Yuhua ^a   Pan, Yijun ^b   Taylor, Aryn ^b   Radakrishnan, Sharmini ^c   Luo, Feijun ^d   Pincus, Harold Alan ^e   Schackman, Bruce R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Molecular Biology and Genetics   (United States)

^c ABT ASSOCIATES   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE; CONTROLLED SUBSTANCE; NARCOTIC ANALGESIC AGENT;

ADULT; AMBULATORY CARE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; ELECTRONIC PRESCRIBING; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; OUTCOME ASSESSMENT; PAIN; PRESCRIPTION; PRESCRIPTION DRUG MONITORING PPROGRAM; PROGRAM EVALUATION; REDUCTION; DRUG OVERDOSE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PRESCRIPTION DRUG MONITORING PROGRAM; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADULT; ANALGESICS, OPIOID; CONTROLLED SUBSTANCES; DRUG OVERDOSE; DRUG PRESCRIPTIONS; HUMANS; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PRESCRIPTION DRUG MONITORING PROGRAMS; SURVEYS AND QUESTIONNAIRES;

EID: 84973472628     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2015.1673     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention, National Center for Health Statistics. Number and ageadjusted rates of drug-poisoning deaths involving opioid analgesics and heroin: United States, 2000-2014. National Vital Statistics System, Mortality File [Internet]. Atlanta (GA): CDC; [cited 2016 May 16]. Available from: http://www.cdc .gov/nchs/data/health_policy/AADR_drug_poisoning_involving_OA_Heroin_US_2000-2014.pdf
2. Substance Abuse and Mental Health Services Administration. Results from the 2014 National Survey on Drug Use and Health: detailed tables [Internet]. Rockville (MD):SAMHSA; 2015 Sep 10 [cited 2016 May 3]. Available from: http:// www.samhsa.gov/data/sites/ default/files/NSDUH-DetTabs2014/NSDUH-DetTabs2014.pdf
3. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300(22):2613-20.
4. White AG, Birnbaum HG, Schiller M, Tang J, Katz NP. Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care. 2009;15(12):897-906.
5. RTI International. Results from the 2013 National Survey on Drug Use and Health: summary of national findings [Internet]. Rockville (MD):Substance Abuse and Mental Health Services Administration; 2014 [cited 2016 May 3]. (HHS Publication No. [SMA] 14-4863). Available from:http://www.samhsa.gov/data/sites/ default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults 2013.pdf
6. Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR. Characteristics of opioid prescriptions in 2009. JAMA. 2011;305(13):1299-301.
7. Clark T, Eadie J, Kreiner P, Strickler G (Heller School for Social Policy and Management, Brandeis University, Waltham, MA). Prescription drug monitoring programs: an assessment of the evidence for best practices [Internet]. Philadelphia (PA): Pew Charitable Trusts; 2012 Sep 20 [cited 2016 May 3]. Available from: http://www.pewtrusts.org/~/ media/assets/0001/pdmp_update_1312013.pdf
8. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747-54.
9. Paulozzi LJ, Stier DD. Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania. J Public Health Policy. 2010;31(4):422-32.
10. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse. 2009;3:41-51.
11. Simeone R, Holland L. An evaluation of prescription drug monitoring programs [Internet]. Albany (NY):Simeone Associates Inc.; 2006 Sep 1 [cited 2016 May 3]. Available from:http://www.simeoneassociates .com/simeone3.pdf
12. Feldman L, Williams KS, Coates J, Knox M. Awareness and utilization of a prescription monitoring program among physicians. J Pain Palliat Care Pharmacother. 2011; 25(4):313-7.
13. Brady JE, Wunsch H, DiMaggio C, Lang BH, Giglio J, Li G. Prescription drug monitoring and dispensing of prescription opioids. Public Health Rep. 2014;129(2):139-47.
14. Li G, Brady J, Lang B, Giglio J, Wunsch H, DiMaggio C. Prescription drug monitoring and drug overdose mortality. Injury Epidemiology. 2014;1(9):9.
15. Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012; 13(3):434-42.
16. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM.What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014; 145:34-47.
17. Baehren DF, Marco CA, Droz DE, Sinha S, Callan EM, Akpunonu P. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med. 2010;56(1):19-23.
18. Kreiner P, Nikitin R, Shields TP (Heller School for Social Policy and Management, Brandeis University, Waltham, MA). Bureau of Justice Assistance Prescription Drug Monitoring Program performance measures report: January 2009 through June 2012 [Internet]. Washington (DC): Bureau of Justice Assistance; [grantee feedback included 2014 Apr 4; cited 2016 May 3]. Available from: http://www.pdmpexcellence .org/sites/all/pdfs/BJA%20PDMP %20Performance%20Measures %20Report%20Jan%202009%20 to%20June%202012%20FInal_ with%20feedback.pdf
19. Centers for Disease Control and Prevention, National Center for Health Statistics. 2010 NAMCS micro-data file documentation [Internet]. Hyattsville (MD): NCHS [cited 2016 May 3]. Available from:ftp://ftp.cdc.gov/pub/Health_ statistics/NCHs/Dataset_Documentation/NAMCS/doc2010.pdf
20. Centers for Disease Control and Prevention, National Center for Health Statistics. NAMCS data collection and processing [Internet]. Hyattsville (MD): NCHS; [last reviewed 2015 Nov 6; cited 2016 May 3]. Available from: http:// www.cdc.gov/nchs/ahcd/ahcd_ data_collection.htm#namcs_ collection
21. Centers for Disease Control and Prevention, National Center for Health Statistics. Trend analysis using NAMCS and NHAMCS drug data [Internet]. Hyattsville (MD): NCHS; [last reviewed 2015 Nov 6; cited 2016 May 3]. Available from: http://www .cdc.gov/nchs/ahcd/trend_analysis .htm
22. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299(1):70-8.
23. To access the Appendix, click on the Appendix link in the box to the right of the article online.
24. National Alliance for Model State Drug Laws [home page on the Internet]. Charlottesville (VA):NAMSDL; c 2016 [cited 2016 May 3]. Available from: http://www.namsdl .org/
25. Paulozzi LJ, Mack KA, Hockenberry JM. Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines-United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(26):563-8.
26. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276-86.
27. Prescription Drug Monitoring Program Center of Excellence at Brandeis. Mandating PDMP participation by medical providers: current status and experience in selected states [Internet]. Waltham (MA):The Center; 2014 Oct [cited 2016 May 3]. (COE Briefing). Available from: http://www.pdmpexcellence .org/sites/all/pdfs/COE_briefing_ mandates_2nd_rev.pdf
28. Prescription Drug Monitoring Program Center of Excellence at Brandeis. Options for unsolicited reporting [Internet].Waltham (MA):The Center; 2014 Jan [cited 2016 May 3]. (Guidance on PDMP Best Practices). Available from: http:// pdmpexcellence.org/sites/all/pdfs/Brandeis_COE_Guidance:on_Unsolicited_Reporting_final.pdf
29. Prescription Drug Monitoring Program Center of Excellence at Brandeis. PDMP delegate account systems [Internet]. Waltham (MA):The Center; 2015 May [cited 2016 May 3]. (COE Briefing). Available from: http://www.pdmpexcellence .org/sites/all/pdfs/COE%20Briefing%20on%20Delegate%20Account%20Systems.pdf
30. Wastila L, Bishop C. The influence of multiple copy prescription programs on analgesic utilization. J Pharm Care Symptom Control. 1996;4(3):3-19.
31. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: rescheduling of hydrocodone combination products from Schedule III to Schedule II. Final rule. Fed Regist. 2014;79(163):49661-82.
32. Barrett K, Watson A. Physician perspectives on a pilot prescription monitoring program. J Pain Palliat Care Pharmacother. 2005;19(3):5-13.
33. Ulbrich TR, Dula CA, Green CG, Porter K, Bennett MS. Factors influencing community pharmacists' enrollment in a state prescription monitoring program. J Am Pharm Assoc (2003). 2010;50(5):588-94.